Overview

Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions

Status:
COMPLETED
Trial end date:
2023-06-14
Target enrollment:
Participant gender:
Summary
To assess the bioequivalence of lamotrigine from Lamotrigin Desitin 100 mg tablets and Lamictal 100 mg Tablet.
Phase:
PHASE1
Details
Lead Sponsor:
Desitin Arzneimittel GmbH
Collaborator:
BioPharma Services Inc.
Treatments:
Lamotrigine